Exact Mass: 373.1402

Exact Mass Matches: 373.1402

Found 93 metabolites which its exact mass value is equals to given mass value 373.1402, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Prochlorperazine

2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine

C20H24ClN3S (373.1379)


Prochlorperazine is only found in individuals that have used or taken this drug. It is a phenothiazine antipsychotic used principally in the treatment of nausea; vomiting; and vertigo. It is more likely than chlorpromazine to cause extrapyramidal disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)The mechanism of action of prochlorperazine has not been fully determined, but may be primarily related to its antidopaminergic effects. Prochlorperazine blocks the D2 somatodendritic autoreceptor, resulting in the blockade of postsynaptic dopamine receptors in the mesolimbic system and an increased dopamine turnover. Prochlorperazine also has anti-emetic effects, which can be attributed to dopamine blockade in the chemoreceptor trigger zone. Prochlorperazine also blocks anticholinergic and alpha-adrenergic receptors, the blockade of alpha(1)-adrenergic receptors resulting in sedation, muscle relaxation, and hypotension. N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent > C740 - Phenothiazine D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D005765 - Gastrointestinal Agents > D000932 - Antiemetics

   

Olopatadine Hydrochloride

Olopatadine Hydrochloride

C21H24ClNO3 (373.1445)


D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents D018926 - Anti-Allergic Agents Olopatadine hydrochloride (ALO4943A) is a histamine blocker used to treat allergic conjunctivitis. Target: Histamine Receptor Olopatadine hydrochloride (ALO4943A) is one of the second-generation histamine H1 receptor antagonists that are treated for allergic disorders. Olopatadine hydrochloride (ALO4943A) significantly inhibited the ear swelling and the increased production of IL-4, IL-1beta, IL-6, GM-CSF and NGF in the lesioned ear [1]. Olopatadine hydrochloride (ALO4943A) was highly and rapidly absorbed in healthy human volunteers. The urinary excretion of Olopatadine hydrochloride (ALO4943A) accounted for not less than 58\% and the contribution of metabolism was considerably low in the clearance of olopatadine in humans. Olopatadine hydrochloride (ALO4943A) is one of the few renal clearance drugs in antiallergic drugs. Olopatadine hydrochloride (ALO4943A) was shown to be useful for the treatment of allergic rhinitis and chronic urticaria in double-blind clinical trials [2]. Olopatadine hydrochloride (ALO4943A) inhibits histamine release in a concentration-dependent fashion (IC50 = 559 microM) from human conjunctival mast cell preparations in vitro. Passive anaphylaxis in guinea pig conjunctiva was attenuated by Olopatadine hydrochloride (ALO4943A) applied 30 min prior to intravenous or topical ocular antigen challenge (ED50 values 0.0067\% and 0.0170\%, w/v, respectively) [3].

   
   

Marinacarboline B

Marinacarboline B

C22H19N3O3 (373.1426)


A natural product found in Marinactinospora thermotolerans.

   
   
   
   

Isosalviamine C

Isosalviamine C

C23H19NO4 (373.1314)


   

acetic acid (2R,3R,4R,5R)-4,5-diacetoxy-2-acetoxymethyl-1-acetyl-piperidin-3-yl ester|peracetyl-1-deoxymannonojirimycin

acetic acid (2R,3R,4R,5R)-4,5-diacetoxy-2-acetoxymethyl-1-acetyl-piperidin-3-yl ester|peracetyl-1-deoxymannonojirimycin

C16H23NO9 (373.1373)


   
   
   
   

ortho-topolin riboside

ortho-topolin riboside

C17H19N5O5 (373.1386)


   

Angustoline acetate

Angustoline acetate

C22H19N3O3 (373.1426)


   

Cystodytin E

Cystodytin E

C22H19N3O3 (373.1426)


An alkaloid that is an enamide obtained by the formal condensation of tiglic acid with 6-(2-amino-1-hydroxyethyl)-4H-pyrido[2,3,4-kl]acridin-4-one. It is isolated from the Okinawan marine tunicate Cystodytes dellechiajei and exhibits cytotoxicity against human epidermoid carcinoma KB cells

   

m-Topolin riboside

m-Topolin riboside

C17H19N5O5 (373.1386)


   

Cystodytin D

Cystodytin D

C22H19N3O3 (373.1426)


An alkaloid that is an enamide obtained by the formal condensation of 3-methylbut-2-enoic acid with 6-(2-amino-1-hydroxyethyl)-4H-pyrido[2,3,4-kl]acridin-4-one. It is isolated from the Okinawan marine tunicate Cystodytes dellechiajei and exhibits cytotoxicity against human epidermoid carcinoma KB cells.

   
   
   
   
   
   

prochlorperazine

prochlorperazine

C20H24ClN3S (373.1379)


N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent > C740 - Phenothiazine D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D005765 - Gastrointestinal Agents > D000932 - Antiemetics

   

8-2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-guanine

8-2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-guanine

C18H15N9O1 (373.14)


   
   
   
   
   
   
   
   
   

PHOME

(3-phenyl-oxiranyl)-acetic acid cyano-(6-methoxy-naphthalen-2-yl)-methyl ester

C23H19NO4 (373.1314)


   

4-((((9H-FLUOREN-9-YL)METHOXY)CARBONYL)(METHYL)AMINO)BENZOIC ACID

4-((((9H-FLUOREN-9-YL)METHOXY)CARBONYL)(METHYL)AMINO)BENZOIC ACID

C23H19NO4 (373.1314)


   

2-[(1-Acetyl-2-oxopropyl)thio]-N-cyclohexyl-1H-benzimidazole-1-carboxamide

2-[(1-Acetyl-2-oxopropyl)thio]-N-cyclohexyl-1H-benzimidazole-1-carboxamide

C19H23N3O3S (373.146)


   

alpha-Hydroxy-alpha-phenylbenzeneacetic acid (3-endo)-8-azabicyclo[3.2.1]oct-3-yl ester hydrochloride

alpha-Hydroxy-alpha-phenylbenzeneacetic acid (3-endo)-8-azabicyclo[3.2.1]oct-3-yl ester hydrochloride

C21H24ClNO3 (373.1445)


   

FMOC-2-METHYLAMINOBENZOIC ACID

FMOC-2-METHYLAMINOBENZOIC ACID

C23H19NO4 (373.1314)


   

5-[bis(1-isocyanato-1-cyclohexa-2,4-dienyl)methyl]-5-isocyanato-cyclohexa-1,3-diene

5-[bis(1-isocyanato-1-cyclohexa-2,4-dienyl)methyl]-5-isocyanato-cyclohexa-1,3-diene

C22H19N3O3 (373.1426)


   

Fmoc-D-Phg-OH

Fmoc-D-Phg-OH

C23H19NO4 (373.1314)


   

4-IMIDAZO[2,1-B][1,3]THIAZOL-6-YLANILINE

4-IMIDAZO[2,1-B][1,3]THIAZOL-6-YLANILINE

C23H19NO4 (373.1314)


   

(1s,2s)-2-(anthracene-2,3-dicarboximido)cyclohexanecarboxylic acid

(1s,2s)-2-(anthracene-2,3-dicarboximido)cyclohexanecarboxylic acid

C23H19NO4 (373.1314)


   

(1R,2R)-2-(Anthracene-2,3-dicarboximido)cyclohexanecarboxylic Acid

(1R,2R)-2-(Anthracene-2,3-dicarboximido)cyclohexanecarboxylic Acid

C23H19NO4 (373.1314)


   
   

Fmoc-3-Aminomethylbenzoic acid

Fmoc-3-Aminomethylbenzoic acid

C23H19NO4 (373.1314)


   

2,5-bis(4-biphenylyl)oxazole

2,5-bis(4-biphenylyl)oxazole

C27H19NO (373.1467)


   

N6-Benzoyl-2-deoxyadenosine

N6-Benzoyl-2-deoxyadenosine

C17H19N5O5 (373.1386)


   

Fmoc-(P-aminophenyl)acetic acid

Fmoc-(P-aminophenyl)acetic acid

C23H19NO4 (373.1314)


   

Fmoc-4-Amb-OH

Fmoc-4-Amb-OH

C23H19NO4 (373.1314)


   

Src Inhibitor-1

Src Kinase Inhibitor I

C22H19N3O3 (373.1426)


   

4-((Biotinoyl)amino)Butyric acid

4-((Biotinoyl)amino)Butyric acid

C15H23N3O6S (373.1307)


   

(2S,4R)-1-(TERT-BUTOXYCARBONYL)-4-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXYLIC ACID

(2S,4R)-1-(TERT-BUTOXYCARBONYL)-4-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXYLIC ACID

C18H22F3NO4 (373.1501)


   

Proroxan hydrochloride

Proroxan hydrochloride

C21H24ClNO3 (373.1445)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs

   

6-methyl-2-[[(4-methylanilino)-oxomethyl]amino]-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carboxylic acid ethyl ester

6-methyl-2-[[(4-methylanilino)-oxomethyl]amino]-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carboxylic acid ethyl ester

C19H23N3O3S (373.146)


   

1,3-diethyl-6-methyl-N-(2-methylphenyl)-2-oxo-5-benzimidazolesulfonamide

1,3-diethyl-6-methyl-N-(2-methylphenyl)-2-oxo-5-benzimidazolesulfonamide

C19H23N3O3S (373.146)


   

2-(4-Methoxyphenyl)-4-(4-methoxyphenyl)imino-1-benzopyran-6-ol

2-(4-Methoxyphenyl)-4-(4-methoxyphenyl)imino-1-benzopyran-6-ol

C23H19NO4 (373.1314)


   

3-methyl-N-{4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl}benzamide

3-methyl-N-{4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl}benzamide

C19H23N3O3S (373.146)


   

4-[[3-oxo-2-(3-pyridinyl)-1H-isoindol-1-yl]amino]benzoic acid ethyl ester

4-[[3-oxo-2-(3-pyridinyl)-1H-isoindol-1-yl]amino]benzoic acid ethyl ester

C22H19N3O3 (373.1426)


   

butyl 4-[5-[(E)-(ethylcarbamothioylhydrazinylidene)methyl]furan-2-yl]benzoate

butyl 4-[5-[(E)-(ethylcarbamothioylhydrazinylidene)methyl]furan-2-yl]benzoate

C19H23N3O3S (373.146)


   

(2,6-Difluorophenyl)-[4-(5-fluoro-2-methyl-1-benzimidazolyl)-1-piperidinyl]methanone

(2,6-Difluorophenyl)-[4-(5-fluoro-2-methyl-1-benzimidazolyl)-1-piperidinyl]methanone

C20H18F3N3O (373.1402)


   

4-[3-(1,3-Benzodioxol-5-ylmethylamino)-7-methyl-2-imidazo[1,2-a]pyridinyl]phenol

4-[3-(1,3-Benzodioxol-5-ylmethylamino)-7-methyl-2-imidazo[1,2-a]pyridinyl]phenol

C22H19N3O3 (373.1426)


   

6-[[[1-(2-methoxy-5-methylphenyl)-5-tetrazolyl]thio]methyl]-N2,N2-dimethyl-1,3,5-triazine-2,4-diamine

6-[[[1-(2-methoxy-5-methylphenyl)-5-tetrazolyl]thio]methyl]-N2,N2-dimethyl-1,3,5-triazine-2,4-diamine

C15H19N9OS (373.1433)


   
   
   
   
   

4-Nitrobenzoic acid (3,3,7,8-tetramethyl-1,5-dihydro-[1,3]dioxepino[5,6-c]pyridin-7-ium-9-yl) ester

4-Nitrobenzoic acid (3,3,7,8-tetramethyl-1,5-dihydro-[1,3]dioxepino[5,6-c]pyridin-7-ium-9-yl) ester

C19H21N2O6+ (373.14)


   

N-[4-[2-methyl-4-(2-methylpropyl)-5-oxo-2-oxolanyl]-2-thiazolyl]benzohydrazide

N-[4-[2-methyl-4-(2-methylpropyl)-5-oxo-2-oxolanyl]-2-thiazolyl]benzohydrazide

C19H23N3O3S (373.146)


   

3,5-dimethyl-4-[[(1R,5S)-7-[4-[(E)-prop-1-enyl]phenyl]-3,6-diazabicyclo[3.1.1]heptan-6-yl]sulfonyl]-1,2-oxazole

3,5-dimethyl-4-[[(1R,5S)-7-[4-[(E)-prop-1-enyl]phenyl]-3,6-diazabicyclo[3.1.1]heptan-6-yl]sulfonyl]-1,2-oxazole

C19H23N3O3S (373.146)


   

[(2S,3S)-6-methylsulfonyl-3-phenyl-1-(2-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-2-yl]methanol

[(2S,3S)-6-methylsulfonyl-3-phenyl-1-(2-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-2-yl]methanol

C19H23N3O3S (373.146)


   

[(2S,3R)-1-methylsulfonyl-3-phenyl-6-(2-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-2-yl]methanol

[(2S,3R)-1-methylsulfonyl-3-phenyl-6-(2-pyridinylmethyl)-1,6-diazaspiro[3.3]heptan-2-yl]methanol

C19H23N3O3S (373.146)


   
   
   
   
   
   

N6-(4-Hydroxybenzyl)adenosine

N6-(4-Hydroxybenzyl)adenosine

C17H19N5O5 (373.1386)


N6-(4-Hydroxybenzyl)adenosine is a inhibitor of platelet aggregation induced in vitro by collagen and their activity range was demonstrated (IC50: 6.77-141 μM). IC50 value: 6.77-141 μM Target: P2Y12receptor Anti-aggregation activity of N6-(4-Hydroxybenzyl)adenosine could involve an interaction with the P2Y12receptor binding site. N6-(4-Hydroxybenzyl)adenosine is a inhibitor of platelet aggregation induced in vitro by collagen and their activity range was demonstrated (IC50: 6.77-141 μM). IC50 value: 6.77-141 μM Target: P2Y12receptor Anti-aggregation activity of N6-(4-Hydroxybenzyl)adenosine could involve an interaction with the P2Y12receptor binding site.

   

Osavampator

Osavampator

C19H23N3O3S (373.146)


Osavampator (TAK-653) is a AMPA receptor positive allosteric modulator. Osavampator selectively binds to AMPA-R in a glutamate-dependent manner and induces Ca2+ influx in hGluA1i CHO cells (EC50 = 3.3 μM). Osavampator improves learning and memory in many models. Osavampator is can be used for the research of depressive disorders[1][2]. Osavampator (TAK-653) is a AMPA receptor positive allosteric modulator. Osavampator selectively binds to AMPA-R in a glutamate-dependent manner and induces Ca2+ influx in hGluA1i CHO cells (EC50 = 3.3 μM). Osavampator improves learning and memory in many models. Osavampator is can be used for the research of depressive disorders[1][2].

   

[(2r,3r,4r,5r)-1-acetyl-3,4,5-tris(acetyloxy)piperidin-2-yl]methyl acetate

[(2r,3r,4r,5r)-1-acetyl-3,4,5-tris(acetyloxy)piperidin-2-yl]methyl acetate

C16H23NO9 (373.1373)


   

2-[4-(3-chloro-1h-pyrrol-2-yl)-3-methylbuta-1,3-dien-1-yl]-6-methoxy-3-methyl-5-(2-methylbut-3-en-2-yl)pyran-4-one

2-[4-(3-chloro-1h-pyrrol-2-yl)-3-methylbuta-1,3-dien-1-yl]-6-methoxy-3-methyl-5-(2-methylbut-3-en-2-yl)pyran-4-one

C21H24ClNO3 (373.1445)


   

(14r,16r)-14-hydroxy-16-isopropyl-15-oxa-2,12,18-triazahexacyclo[11.8.1.1¹⁴,¹⁸.0³,⁸.0⁹,²².0²¹,²³]tricosa-1,3(8),4,6,9(22),10,12,21(23)-octaen-17-one

(14r,16r)-14-hydroxy-16-isopropyl-15-oxa-2,12,18-triazahexacyclo[11.8.1.1¹⁴,¹⁸.0³,⁸.0⁹,²².0²¹,²³]tricosa-1,3(8),4,6,9(22),10,12,21(23)-octaen-17-one

C22H19N3O3 (373.1426)


   

[1-acetyl-3,4,5-tris(acetyloxy)piperidin-2-yl]methyl acetate

[1-acetyl-3,4,5-tris(acetyloxy)piperidin-2-yl]methyl acetate

C16H23NO9 (373.1373)


   

14-hydroxy-16-isopropyl-15-oxa-2,12,18-triazahexacyclo[11.8.1.1¹⁴,¹⁸.0³,⁸.0⁹,²².0²¹,²³]tricosa-1,3(8),4,6,9(22),10,12,21(23)-octaen-17-one

14-hydroxy-16-isopropyl-15-oxa-2,12,18-triazahexacyclo[11.8.1.1¹⁴,¹⁸.0³,⁸.0⁹,²².0²¹,²³]tricosa-1,3(8),4,6,9(22),10,12,21(23)-octaen-17-one

C22H19N3O3 (373.1426)


   

n-(2-hydroxy-2-{12-oxo-8,14-diazatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2(7),3,5,8,10,13,15-octaen-10-yl}ethyl)-3-methylbut-2-enimidic acid

n-(2-hydroxy-2-{12-oxo-8,14-diazatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2(7),3,5,8,10,13,15-octaen-10-yl}ethyl)-3-methylbut-2-enimidic acid

C22H19N3O3 (373.1426)


   

(14s,16s)-14-hydroxy-16-isopropyl-15-oxa-2,12,18-triazahexacyclo[11.8.1.1¹⁴,¹⁸.0³,⁸.0⁹,²².0²¹,²³]tricosa-1,3(8),4,6,9(22),10,12,21(23)-octaen-17-one

(14s,16s)-14-hydroxy-16-isopropyl-15-oxa-2,12,18-triazahexacyclo[11.8.1.1¹⁴,¹⁸.0³,⁸.0⁹,²².0²¹,²³]tricosa-1,3(8),4,6,9(22),10,12,21(23)-octaen-17-one

C22H19N3O3 (373.1426)


   

2-(hydroxymethyl)-5-(6-{[(3-hydroxyphenyl)methyl]amino}purin-9-yl)oxolane-3,4-diol

2-(hydroxymethyl)-5-(6-{[(3-hydroxyphenyl)methyl]amino}purin-9-yl)oxolane-3,4-diol

C17H19N5O5 (373.1386)


   

(2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-2-[(4-hydroxyphenyl)methyl]oxolane-3,4-diol

(2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-2-[(4-hydroxyphenyl)methyl]oxolane-3,4-diol

C17H19N5O5 (373.1386)


   

(2e)-n-(2-hydroxy-2-{12-oxo-8,14-diazatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2(7),3,5,8,10,13,15-octaen-10-yl}ethyl)-2-methylbut-2-enimidic acid

(2e)-n-(2-hydroxy-2-{12-oxo-8,14-diazatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2(7),3,5,8,10,13,15-octaen-10-yl}ethyl)-2-methylbut-2-enimidic acid

C22H19N3O3 (373.1426)


   

(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-{[(3-hydroxyphenyl)methyl]amino}purin-9-yl)oxolane-3,4-diol

(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-{[(3-hydroxyphenyl)methyl]amino}purin-9-yl)oxolane-3,4-diol

C17H19N5O5 (373.1386)


   

methyl 3-{5,17-dimethyl-3,8-dioxa-10-azapentacyclo[10.8.0.0²,⁶.0⁷,¹¹.0¹³,¹⁸]icosa-1(20),2(6),4,7(11),9,12,14,16,18-nonaen-9-yl}propanoate

methyl 3-{5,17-dimethyl-3,8-dioxa-10-azapentacyclo[10.8.0.0²,⁶.0⁷,¹¹.0¹³,¹⁸]icosa-1(20),2(6),4,7(11),9,12,14,16,18-nonaen-9-yl}propanoate

C23H19NO4 (373.1314)


   

[(2r,3r,4r,5s)-1-acetyl-3,4,5-tris(acetyloxy)piperidin-2-yl]methyl acetate

[(2r,3r,4r,5s)-1-acetyl-3,4,5-tris(acetyloxy)piperidin-2-yl]methyl acetate

C16H23NO9 (373.1373)


   

(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-{[(4-hydroxyphenyl)methyl]amino}purin-9-yl)oxolane-3,4-diol

(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-{[(4-hydroxyphenyl)methyl]amino}purin-9-yl)oxolane-3,4-diol

C17H19N5O5 (373.1386)


   

2-[(1e,3e)-4-(3-chloro-1h-pyrrol-2-yl)-3-methylbuta-1,3-dien-1-yl]-6-methoxy-3-methyl-5-(2-methylbut-3-en-2-yl)pyran-4-one

2-[(1e,3e)-4-(3-chloro-1h-pyrrol-2-yl)-3-methylbuta-1,3-dien-1-yl]-6-methoxy-3-methyl-5-(2-methylbut-3-en-2-yl)pyran-4-one

C21H24ClNO3 (373.1445)


   

2-(hydroxymethyl)-5-(6-{[(4-hydroxyphenyl)methyl]amino}purin-9-yl)oxolane-3,4-diol

2-(hydroxymethyl)-5-(6-{[(4-hydroxyphenyl)methyl]amino}purin-9-yl)oxolane-3,4-diol

C17H19N5O5 (373.1386)